midazolam has been researched along with citalopram in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.76) | 18.2507 |
2000's | 11 (52.38) | 29.6817 |
2010's | 9 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Faller, B; Trunzer, M; Zimmerlin, A | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Artursson, P; Mateus, A; Matsson, P | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Mäenpää, J; Pelkonen, O; Raunio, H; Rautio, A; Taavitsainen, P | 1 |
Baker, SD; Bose, S; Levsky, M; Masullo, LN; Miller, MA | 1 |
Graudins, A; Green, D; Morris, E | 1 |
Abouchedid, R; Archer, JR; Dargan, PI; Dines, A; Ho, JH; Hudson, S; Wood, DM | 1 |
Hloch, O; Hložek, T; Horsley, R; Židková, M | 1 |
Cuypers, E; Somers, T; Vandenbosch, M | 1 |
2 review(s) available for midazolam and citalopram
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Topics: Antipyrine; Citalopram; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Humans; Inactivation, Metabolic; Liver; Midazolam; Smoking; Substrate Specificity | 1998 |
19 other study(ies) available for midazolam and citalopram
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
Topics: Chromatography, Liquid; Drug Design; Humans; Likelihood Functions; Microsomes, Liver; Pharmacokinetics; Tandem Mass Spectrometry | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Clinical course and toxicokinetic data following isolated citalopram overdose in an infant.
Topics: Charcoal; Citalopram; Drug Overdose; Female; Humans; Hypnotics and Sedatives; Infant; Intensive Care Units, Pediatric; Midazolam; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Chlorpromazine; Citalopram; Combined Modality Therapy; Dopamine Agonists; Drug Overdose; Female; Humans; Hypnotics and Sedatives; Hypothermia, Induced; Infusions, Intravenous; Midazolam; Neuroleptic Malignant Syndrome; Olanzapine; Respiration, Artificial; Treatment Outcome | 2009 |
Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Topics: Adamantane; Administration, Intravenous; Anti-Anxiety Agents; Cannabinoid Receptor Agonists; Citalopram; Female; Fluoxetine; Hallucinations; Hallucinogens; Humans; Indazoles; Indoles; Lysergic Acid Diethylamide; Midazolam; Psychomotor Agitation; Quinolines; Seizures; Tachycardia; Time Factors; Young Adult | 2016 |
Near-fatal Intoxication with the "New" Synthetic Opioid U-47700: The First Reported Case in the Czech Republic.
Topics: Adult; Benzamides; Benzodiazepines; Chromatography, Liquid; Citalopram; Czech Republic; Drug Overdose; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Illicit Drugs; Male; Mass Spectrometry; Midazolam; Substance Abuse Detection | 2019 |
Distribution of clomipramine, citalopram, midazolam, and metabolites in skeletal tissue after chronic dosing in rats.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Bone and Bones; Chromatography, High Pressure Liquid; Citalopram; Clomipramine; Limit of Detection; Male; Midazolam; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |